AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2017
May 27, 2017
31289_dirs_2017-05-26_18272fb7-7567-4d97-aca3-f1221ac8a004.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2017-05-25
Reporting Person: Davis Todd C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-05-25 | Common Stock | A | 666 | $0.0 | Acquired | 70807 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-25 | Non-Qualified Stock Option (right to buy) | $113.5 | A | 2456 | Acquired | 2027-05-25 | Common Stock (2456) | Direct |
Footnotes
F1: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017 Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.